(0.31%) 5 115.57 points
(0.31%) 38 360 points
(0.33%) 15 981 points
(-0.94%) $83.06
(5.51%) $2.03
(0.36%) $2 355.60
(0.41%) $27.65
(4.01%) $959.05
(-0.23%) $0.933
(-0.40%) $10.98
(-0.55%) $0.796
(1.69%) $93.43
2 days till quarter result
(bmo 2024-05-01)
Expected move: +/- 17.61%
@ $3.65
発行日: 15 2月 2024 @ 03:53
リターン: 33.70%
前回のシグナル: 2月 14 - 01:05
前回のシグナル:
リターン: -1.62 %
Live Chart Being Loaded With Signals
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform...
Stats | |
---|---|
本日の出来高 | 197 446 |
平均出来高 | 896 177 |
時価総額 | 596.75M |
EPS | $0 ( 2024-03-06 ) |
次の収益日 | ( $-0.180 ) 2024-05-01 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -9.04 |
ATR14 | $0.00800 (0.16%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-03 | Moran Kyle | Sell | 15 630 | Ordinary Shares |
2024-02-05 | Francis Chris | Buy | 286 400 | Share Option (right to buy) |
2024-02-05 | Bolno Paul | Buy | 1 008 600 | Share Option (right to buy) |
2024-02-05 | Moran Kyle | Buy | 371 500 | Share Option (right to buy) |
2024-02-05 | Vargeese Chandra | Buy | 361 700 | Share Option (right to buy) |
INSIDER POWER |
---|
98.57 |
Last 99 transactions |
Buy: 37 730 786 | Sell: 301 457 |
ボリューム 相関
WAVE Life Sciences Ltd 相関
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
WAVE Life Sciences Ltd 相関 - 通貨/商品
WAVE Life Sciences Ltd 財務諸表
Annual | 2023 |
収益: | $113.31M |
総利益: | $104.10M (91.88 %) |
EPS: | $-0.540 |
FY | 2023 |
収益: | $113.31M |
総利益: | $104.10M (91.88 %) |
EPS: | $-0.540 |
FY | 2022 |
収益: | $3.65M |
総利益: | $-6.47M (-177.17 %) |
EPS: | $-2.05 |
FY | 2021 |
収益: | $40.96M |
総利益: | $0.00 (0.00 %) |
EPS: | $-2.36 |
Financial Reports:
No articles found.
WAVE Life Sciences Ltd
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington's disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; and ATXN3, a discovery stage program for the treatment of spinocerebellar ataxia 3, as well as multiple preclinical programs for CNS disorders. In addition, it focuses on developing GalNAc-conjugated AIMers to treat hepatic indications comprising Alpha-1 antitrypsin deficiency (AATD); and two preclinical programs, such as Usher syndrome type 2A (USH2A) and retinitis pigmentosa due to a P23H mutation in the RHO gene (RhoP23H) for the treatment of retinal diseases. It has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, University of Oxford, University of Massachusetts, Western Washington University, Grenoble Institute of Neurosciences, IRBM S.p.A, University of Louisville, and University College London. The company was incorporated in 2012 and is based in Singapore.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。